What happened
Samsung Biologics updated a previously disclosed supply contract, now worth US$548M, about 18.38% of its recent annual revenue, running through Dec 2031.
For context, this single contract equals about 18.38% of the company's most recent annual revenue.
| Counterparty | Disclosed |
|---|---|
| Contract value | US$548M |
| vs. recent revenue | 18.38% |
| Through | Dec 2031 (from Apr 2025) |
| Filed | 2026-06-17, [Amended] Supply contract signed |
| Source | DART rcept 20260617800458 → open original filing |
Source: DART. Information only, not investment advice.